Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

Treatments with therapeutic phlebotomy and hydroxyurea are associated with improved overall survival and decreased risk of thrombosis in older patients with polycythemia vera, according to a recent ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients (HealthDay News) — Among older patients with polycythemia vera (PV), therapeutic phlebotomy and ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PTG-300, a ...

Please provide your email address to receive an email when new articles are posted on . Verstovsek and colleagues sought to confirm the benefits of ruxolitinib (Jakafi, Incyte) — a JAK 1 and JAK 2 ...

DEAR DR. ROACH: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his ...